A Locke Lord team led by Keith Parr (Chicago) secured an order and judgment of noninfringement in the U.S. District Court of New Jersey for Lupin Limited, a multinational pharmaceutical company. Plaintiffs alleged that the Abbreviated New Drug Application (ANDA) filed by Lupin Limited with the U.S. Food and Drug Administration seeking approval to market a proposed generic version of Erleada, a medication which is used in the treatment of prostate cancer, infringed the asserted patent. After testing samples of Lupin’s proposed ANDA product, plaintiffs agreed to the entry of a stipulated order and judgment that Lupin Limited’s proposed generic version of Johnson & Johnson’s Erleada product will not infringe the asserted patent for the prostate cancer treatment. Additional support was provided by Michael Gaertner, James Peterka, Nina Vachhani, Jacob Britz (all of Chicago) and Zhibin Li (New York).
Posted on December 26, 2023